Amphastar Pharmaceuticals (FRA:29A) Total Liabilities : €829.8 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Amphastar Pharmaceuticals Total Liabilities?

Amphastar Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €829.8 Mil.

Amphastar Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 (€889.68 Mil) to Dec. 2023 (€800.99 Mil) but then increased from Dec. 2023 (€800.99 Mil) to Mar. 2024 (€829.80 Mil).

Amphastar Pharmaceuticals's annual Total Liabilities increased from Dec. 2021 (€200.02 Mil) to Dec. 2022 (€201.38 Mil) and increased from Dec. 2022 (€201.38 Mil) to Dec. 2023 (€800.99 Mil).

Amphastar Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Amphastar Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amphastar Pharmaceuticals Total Liabilities Chart

Amphastar Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

143.50

150.03

200.02

201.38

800.99

Amphastar Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															210.22	728.28	889.68	800.99	829.80

Amphastar Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Amphastar Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	206.698	+	(567.898	+	20.832
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.563	+	0)
	=	801.0

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1387.34	-	586.349
	=	801.0

Amphastar Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	234.755	+	(572.925	+	16.543
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.581	+	0)
	=	829.8

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1448.372	-	618.568
	=	829.8

Amphastar Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Amphastar Pharmaceuticals (FRA:29A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amphastar Pharmaceuticals Inc (FRA:29A) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AMPH:USA 29A:Germany

Address

11570 6th Street, Rancho Cucamonga, CA, USA, 91730

Website

http://www.amphastar.com

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Amphastar Pharmaceuticals (FRA:29A) Headlines

No Headlines